

# Ho Jung An

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7574378/publications.pdf>

Version: 2024-02-01

39  
papers

691  
citations

758635

12  
h-index

580395

25  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1102  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495.	0.8	233
2	Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2012, 18, 1406-1414.	1.3	67
3	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9414.	1.8	46
4	Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1876-1882.	1.4	34
5	The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. <i>Pathology Research and Practice</i> , 2016, 212, 357-364.	1.0	30
6	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial. <i>Thoracic Cancer</i> , 2020, 11, 62-71.	0.8	27
7	DeepBTS: Prediction of Recurrence-free Survival of Non-small Cell Lung Cancer Using a Time-binned Deep Neural Network. <i>Scientific Reports</i> , 2020, 10, 1952.	1.6	25
8	Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 277-283.	1.3	23
9	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72.	0.9	22
10	DeepRePath: Identifying the Prognostic Features of Early-Stage Lung Adenocarcinoma Using Multi-Scale Pathology Images and Deep Convolutional Neural Networks. <i>Cancers</i> , 2021, 13, 3308.	1.7	21
11	Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1632-1638.	1.3	16
12	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	1.3	14
13	A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 713-720.	2.9	13
14	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	1.2	12
15	Ramotetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Research and Treatment</i> , 2020, 52, 907-916.	1.3	12
16	Experience of Advance Directives in a Hospice Center. <i>Journal of Korean Medical Science</i> , 2015, 30, 151.	1.1	11
17	Factors associated with treatment interruption in elderly patients with cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 156-164.	0.7	10
18	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.	1.3	10

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). <i>Clinical Cancer Research</i> , 2022, 28, 4240-4247.	3.2	10
20	Cascaded Wx: A Novel Prognosis-Related Feature Selection Framework in Human Lung Adenocarcinoma Transcriptomes. <i>Frontiers in Genetics</i> , 2019, 10, 662.	1.1	9
21	High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors. <i>Lung Cancer</i> , 2019, 132, 9-16.	0.9	6
22	Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. <i>Oncology</i> , 2019, 96, 51-58.	0.9	6
23	Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: A prospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 1057-1065.	1.3	6
24	Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 432-434.	0.7	5
25	DeepCUBIT: Predicting Lymphovascular Invasion or Pathological Lymph Node Involvement of Clinical T1 Stage Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Cubical Nodule Transfer Learning Algorithm. <i>Frontiers in Oncology</i> , 2021, 11, 661244.	1.3	5
26	Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer. <i>Pathology Research and Practice</i> , 2017, 213, 949-955.	1.0	4
27	Nebulized Morphine for Intractable Cough in Advanced Cancer: Two Case Reports. <i>Journal of Palliative Medicine</i> , 2015, 18, 278-281.	0.6	3
28	Efficacy of topical epidermal growth factor cream for patients with epidermal growth factor receptor inhibitor-induced acneiform eruption: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2020, 182, 219-221.	1.4	3
29	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6090-6090.	0.8	3
30	Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results. <i>Cancers</i> , 2021, 13, 2337.	1.7	2
31	The effect of platinum based adjuvant chemotherapy on survival in the surgically resected lung adenocarcinoma according to the expression of EGFR mutation specific antibody and c-MET.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7523-7523.	0.8	1
32	Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8574-8574.	0.8	1
33	Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 7431-7438.	1.0	1
34	K-ras mutational status and its clinical implications in Korean colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 641-641.	0.8	0
35	Tumor necrosis as prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 722-722.	0.8	0
36	Clinical implication of mass-spectrometry-based selected reaction monitoring (SRM) assay in non-small cell lung cancer (NSCLC) patients exhibiting ALK gene rearrangement.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22145-e22145.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients. Korean Journal of Internal Medicine, 2016, 31, 134-144.	0.7	0
38	Impact of EGFR mutation status on clinical outcome of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer (NSCLC): Retrospective analysis of Korean nintedanib named-patient usage (NPU) program in NSCLC (KCSG LU14-2).. Journal of Clinical Oncology, 2017, 35, e20638-e20638.	0.8	0
39	Association of the high expressions of SOX2 and IGF-1R signaling molecules in thymic epithelial tumors with shorter overall survival.. Journal of Clinical Oncology, 2018, 36, 8578-8578.	0.8	0